-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 26, the internationally renowned journal "Nature Immunology" published an online article "The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity" by Dr.
APG-115 is a new drug under development under Yasheng Pharmaceutical (6855.
In order to further explore the mechanism of the MDM2-p53 signaling pathway in T cells, the researchers constructed a mouse model that specifically knocked out MDM2 and p53 in T cells.
Before the start of this study, it is still unknown whether MDM2-p53 will affect the anti-tumor immune response mediated by CD8+ T cells.
Dr.
It is reported that Yasheng Pharmaceutical is currently carrying out a phase II clinical trial of APG-115 combined with pembrolizumab to treat patients with tumors that have developed drug resistance or recurrence after PD-1 inhibitor treatment.
Original source:
Original source:Zhou, J.
biodiscover.
com/news/industry/737875.
html" target="_blank" rel="noopener">The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity.
Leave a message here